ReviewAntioxidants (Basel, Switzerland)2020
Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence.
Review in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Epigenetics of Childhood Obesity.Hormone research in paediatrics · 2026Review
- Unlocking the Therapeutic Potential of Ellagitannins: A Comprehensive Review of Key Representatives.Molecules (Basel, Switzerland) · 2025Review
- Dietary Strawberries Improve Serum Antioxidant Profiles in Adults with Prediabetes: A 28-Week Randomized Controlled Crossover Trial.Antioxidants (Basel, Switzerland) · 2025Article
- Multi-Target Modulation of Polyphenols in Diabetic Kidney Disease Therapeutics: A Comprehensive Review.Food science & nutrition · 2025Review
- A Comprehensive Review of the Effects ofPreventive nutrition and food science · 2025Review
- Design and Optimization of a Second-Generation Extruded Snack Using Carrot Waste, Blue Corn Flour, and Ellagic Acid as Functional Ingredients.Foods (Basel, Switzerland) · 2025Article
- Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics.Journal of nanobiotechnology · 2025Review
- What do You Need to Know after Diabetes and before Diabetic Retinopathy?Aging and disease · 2025Review
- Mechanistic Exploration ofBioMed research international · 2025Article
- Review
- A comprehensive investigation of the nano-[CuHeliyon · 2024Article
- In Vitro and Molecular Docking Evaluation of the Anticholinesterase and Antidiabetic Effects of Compounds fromMolecules (Basel, Switzerland) · 2024Article
- A Drug Discovery Approach to a Reveal Novel Antioxidant Natural Source: The Case of Chestnut Burr Biomass.International journal of molecular sciences · 2024Article
- Phytochemical profile, nutritional composition of pomegranate peel and peel extract as a potential source of nutraceutical: A comprehensive review.Food science & nutrition · 2024Review
- A randomized double blind placebo controlled trial to assess the safety and efficacy of a patented fenugreek (Food & nutrition research · 2024Article
- Molecular docking of antidiabetic molecules of libas (In silico pharmacology · 2024Article
- Ellagic Acid Prevents α-Synuclein Spread and Mitigates Toxicity by Enhancing Autophagic Flux in an Animal Model of Parkinson's Disease.Nutrients · 2023Article
- Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity.International journal of molecular sciences · 2023Article
- Chemical Characterization, Antilipidemic Effect and Anti-Obesity Activity ofPlants (Basel, Switzerland) · 2023Article
- Protective Effects ofAntioxidants (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oxidative stress contributes not only to the pathogenesis of type 2 diabetes (T2D) but also to diabetic vascular complications. It follows that antioxidants might contribute to limiting the diabetes burden. In this review we focus on ellagic acid (EA), a compound that can be obtained upon intestinal hydrolysis of dietary ellagitannins, a family of polyphenols naturally found in several fruits and seeds. There is increasing research on cardiometabolic effects of ellagitannins, EA, and urolithins (EA metabolites). We updated research conducted on these compounds and (I) glucose metabolism; (II) inflammation, oxidation, and glycation; and (III) diabetic complications. We included studies testing EA in isolation, extracts or preparations enriched in EA, or EA-rich foods (mostly pomegranate juice). Animal research on the topic, entirely conducted in murine models, mostly reported glucose-lowering, antioxidant, anti-inflammatory, and anti-glycation effects, along with prevention of micro- and macrovascular diabetic complications. Clinical research is incipient and mostly involved non-randomized and low-powered studies, which confirmed the antioxidant and anti-inflammatory properties of EA-rich foods, but without conclusive results on glucose control. Overall, EA-related compounds might be potential agents to limit the diabetes burden, but well-designed human randomized controlled trials are needed to fill the existing gap between experimental and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.